H. T. Hashim, J. Varney, M. A. Ramadhan, A. Sarfraz, Z. Sarfraz, K. Murry, Jaffer Shah, Br, on Watkins, Zanyar Qais, Shoaib Ahmad, M. Y. Essar, Asghar Shah, H. Aiash
{"title":"COVID-19康复患者的失眠","authors":"H. T. Hashim, J. Varney, M. A. Ramadhan, A. Sarfraz, Z. Sarfraz, K. Murry, Jaffer Shah, Br, on Watkins, Zanyar Qais, Shoaib Ahmad, M. Y. Essar, Asghar Shah, H. Aiash","doi":"10.35248/2167-0277.21.10.328","DOIUrl":null,"url":null,"abstract":"Background: Insomnia is a sleeping disorder where individuals have difficulty initiating or maintaining sleep, resulting in nonrefreshing sleep. It may be difficult for patients to fall asleep or remain asleep for the periods recommended for rest. Daytime sleepiness, low energy, irritability, and a depressed mood are usually accompanied by insomnia. Some studies showed that COVID-19 patients could have insomnia during their infection period, and insomnia has been attributed to the stress and depression experienced by the patients during the disease. Methodology: This is a cross-sectional study that includes 1,215 participants from 15 countries. The inclusion criteria were a recovered patient from COVID-19 with no history of psychological disorders of depression, anxiety, stress, insomnia, or any sleep disorder prior to becoming infected. Athena’s Insomnia Scale was used in the diagnosis of insomnia with a score of ≥ 6. Results: The insomnia score of the participants was with a mean and standard deviation of 7.04 ± 4.9. Of the 1215 participants, 943 (77.6%) had a score ≥ of 6 representing insomnia, while 272 (22.4%) did not. One-third of the participants visited a doctor because of their sleep quality, and 352 (29%) took medications to help them take enough sleep. Significant differences across patient characteristics were found across countries. Regression analysis found several patient-level aspects predicting insomnia incidence. The odds ratio (OR) symptomatic headache were OR 1.74 (95% CI 1.17, 2.60; P=.006) and OR 1.79 (95% CI 1.19, 2.72; P=.005), for univariate and multivariate regression, respectively. Country and age were also found to be significant predictors of insomnia incidence in both models. Conclusion: Insomnia can occur after COVID-19 infection. It is typically mild but has the possibly of requiring treatment and follow-up. People from countries with poor healthcare and the elderly have an increased risk of having insomnia after a COVID-19 infection. The present study investigated the characteristics of those presenting with insomnia after COVID-19 infection in a large sample. We also determined that age, country, and symptomatic headache significantly predict insomnia status.","PeriodicalId":73946,"journal":{"name":"Journal of sleep disorders & therapy","volume":"40 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Insomnia Among Recovered COVID-19 Patients\",\"authors\":\"H. T. Hashim, J. Varney, M. A. Ramadhan, A. Sarfraz, Z. Sarfraz, K. Murry, Jaffer Shah, Br, on Watkins, Zanyar Qais, Shoaib Ahmad, M. Y. Essar, Asghar Shah, H. Aiash\",\"doi\":\"10.35248/2167-0277.21.10.328\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Insomnia is a sleeping disorder where individuals have difficulty initiating or maintaining sleep, resulting in nonrefreshing sleep. It may be difficult for patients to fall asleep or remain asleep for the periods recommended for rest. Daytime sleepiness, low energy, irritability, and a depressed mood are usually accompanied by insomnia. Some studies showed that COVID-19 patients could have insomnia during their infection period, and insomnia has been attributed to the stress and depression experienced by the patients during the disease. Methodology: This is a cross-sectional study that includes 1,215 participants from 15 countries. The inclusion criteria were a recovered patient from COVID-19 with no history of psychological disorders of depression, anxiety, stress, insomnia, or any sleep disorder prior to becoming infected. Athena’s Insomnia Scale was used in the diagnosis of insomnia with a score of ≥ 6. Results: The insomnia score of the participants was with a mean and standard deviation of 7.04 ± 4.9. Of the 1215 participants, 943 (77.6%) had a score ≥ of 6 representing insomnia, while 272 (22.4%) did not. One-third of the participants visited a doctor because of their sleep quality, and 352 (29%) took medications to help them take enough sleep. Significant differences across patient characteristics were found across countries. Regression analysis found several patient-level aspects predicting insomnia incidence. The odds ratio (OR) symptomatic headache were OR 1.74 (95% CI 1.17, 2.60; P=.006) and OR 1.79 (95% CI 1.19, 2.72; P=.005), for univariate and multivariate regression, respectively. Country and age were also found to be significant predictors of insomnia incidence in both models. Conclusion: Insomnia can occur after COVID-19 infection. It is typically mild but has the possibly of requiring treatment and follow-up. People from countries with poor healthcare and the elderly have an increased risk of having insomnia after a COVID-19 infection. The present study investigated the characteristics of those presenting with insomnia after COVID-19 infection in a large sample. We also determined that age, country, and symptomatic headache significantly predict insomnia status.\",\"PeriodicalId\":73946,\"journal\":{\"name\":\"Journal of sleep disorders & therapy\",\"volume\":\"40 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of sleep disorders & therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2167-0277.21.10.328\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of sleep disorders & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2167-0277.21.10.328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
背景:失眠是一种睡眠障碍,个体难以开始或维持睡眠,导致睡眠不清爽。患者可能难以入睡或在建议的休息时间内保持睡眠状态。白天嗜睡、精力不足、易怒、情绪低落通常伴有失眠。一些研究表明,COVID-19患者在感染期间可能会失眠,失眠被归因于患者在疾病期间经历的压力和抑郁。方法:这是一项横断面研究,包括来自15个国家的1,215名参与者。纳入标准为COVID-19康复患者,感染前无抑郁、焦虑、压力、失眠或任何睡眠障碍等心理障碍史。采用雅典娜失眠量表(Athena’s Insomnia Scale)进行诊断,评分≥6分。结果:受试者的失眠评分均值和标准差为7.04±4.9。在1215名参与者中,943名(77.6%)得分≥6分代表失眠,而272名(22.4%)没有。三分之一的参与者因为他们的睡眠质量而去看医生,352人(29%)服用药物来帮助他们获得足够的睡眠。不同国家的患者特征存在显著差异。回归分析发现患者层面的几个方面可以预测失眠的发生率。症状性头痛的优势比(OR)为OR 1.74 (95% CI 1.17, 2.60;P= 0.006), OR为1.79 (95% CI 1.19, 2.72;P=.005),分别为单因素和多因素回归。在两种模型中,国家和年龄也被发现是失眠发生率的重要预测因子。结论:新冠肺炎感染后可出现失眠。它通常是轻微的,但有可能需要治疗和随访。来自医疗条件差的国家和老年人在感染COVID-19后失眠的风险增加。本研究在大样本中调查了COVID-19感染后出现失眠的患者的特征。我们还确定年龄、国家和症状性头痛显著预测失眠状态。
Background: Insomnia is a sleeping disorder where individuals have difficulty initiating or maintaining sleep, resulting in nonrefreshing sleep. It may be difficult for patients to fall asleep or remain asleep for the periods recommended for rest. Daytime sleepiness, low energy, irritability, and a depressed mood are usually accompanied by insomnia. Some studies showed that COVID-19 patients could have insomnia during their infection period, and insomnia has been attributed to the stress and depression experienced by the patients during the disease. Methodology: This is a cross-sectional study that includes 1,215 participants from 15 countries. The inclusion criteria were a recovered patient from COVID-19 with no history of psychological disorders of depression, anxiety, stress, insomnia, or any sleep disorder prior to becoming infected. Athena’s Insomnia Scale was used in the diagnosis of insomnia with a score of ≥ 6. Results: The insomnia score of the participants was with a mean and standard deviation of 7.04 ± 4.9. Of the 1215 participants, 943 (77.6%) had a score ≥ of 6 representing insomnia, while 272 (22.4%) did not. One-third of the participants visited a doctor because of their sleep quality, and 352 (29%) took medications to help them take enough sleep. Significant differences across patient characteristics were found across countries. Regression analysis found several patient-level aspects predicting insomnia incidence. The odds ratio (OR) symptomatic headache were OR 1.74 (95% CI 1.17, 2.60; P=.006) and OR 1.79 (95% CI 1.19, 2.72; P=.005), for univariate and multivariate regression, respectively. Country and age were also found to be significant predictors of insomnia incidence in both models. Conclusion: Insomnia can occur after COVID-19 infection. It is typically mild but has the possibly of requiring treatment and follow-up. People from countries with poor healthcare and the elderly have an increased risk of having insomnia after a COVID-19 infection. The present study investigated the characteristics of those presenting with insomnia after COVID-19 infection in a large sample. We also determined that age, country, and symptomatic headache significantly predict insomnia status.